Life Sciences

Sandoz receives FDA warning letter

Pharma Compliance Alert, September 3, 2008

An FDA inspection revealed significant deviations from Good Manufacturing Practice at Novartis’ Sandoz generic unit’s manufacturing facility, according to an agency warning letter.

Post a Comment





Please enter your comment below:


Please enter the text below:

    ePharm5 InDepth
  • ePharm5 InDepth

    EPharm5 e-mail newsletter delivers the top 5 developments in pharma business innovation, with original research, interviews...

  • Complete Guide to Lab Safety, 3rd Ed.

    The third edition of this popular resource makes training and compliance easier by consolidating regulations from all...

Most Popular